Lantheus (LNTH) Competitors $76.83 -1.42 (-1.81%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LNTH vs. TEVA, SMMT, ITCI, GMAB, RDY, VTRS, MRNA, QGEN, ASND, and ROIVShould you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Lantheus vs. Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Teva Pharmaceutical Industries (NYSE:TEVA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment. Which has more risk and volatility, TEVA or LNTH? Teva Pharmaceutical Industries has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TEVA or LNTH? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 1.5% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer TEVA or LNTH? In the previous week, Teva Pharmaceutical Industries had 20 more articles in the media than Lantheus. MarketBeat recorded 35 mentions for Teva Pharmaceutical Industries and 15 mentions for Lantheus. Teva Pharmaceutical Industries' average media sentiment score of 1.11 beat Lantheus' score of 1.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 22 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community favor TEVA or LNTH? Teva Pharmaceutical Industries received 994 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.88% of users gave Teva Pharmaceutical Industries an outperform vote while only 66.15% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133867.88% Underperform Votes63332.12% LantheusOutperform Votes34466.15% Underperform Votes17633.85% Which has preferable earnings and valuation, TEVA or LNTH? Lantheus has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.62B1.14-$1.64B-$1.15-14.57Lantheus$1.54B3.46$326.66M$3.5221.83 Do analysts prefer TEVA or LNTH? Teva Pharmaceutical Industries currently has a consensus target price of $24.43, indicating a potential upside of 45.84%. Lantheus has a consensus target price of $132.67, indicating a potential upside of 72.68%. Given Lantheus' higher possible upside, analysts clearly believe Lantheus is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Lantheus 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TEVA or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Lantheus' return on equity of 44.29% beat Teva Pharmaceutical Industries' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Lantheus 28.57%44.29%23.52% SummaryLantheus beats Teva Pharmaceutical Industries on 10 of the 19 factors compared between the two stocks. Get Lantheus News Delivered to You Automatically Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNTH vs. The Competition Export to ExcelMetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.32B$2.67B$5.43B$8.48BDividend YieldN/A0.75%5.22%4.11%P/E Ratio12.787.6626.8320.05Price / Sales3.4629.09393.86119.28Price / Cash11.9815.7538.2534.62Price / Book6.455.846.874.61Net Income$326.66M-$65.73M$3.22B$248.19M7 Day Performance-2.69%3.68%5.65%2.88%1 Month Performance-24.17%42.31%13.54%15.40%1 Year Performance-7.29%-15.42%18.16%7.68% Lantheus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNTHLantheus4.5045 of 5 stars$76.83-1.8%$132.67+72.7%-1.8%$5.32B$1.54B12.78700Positive NewsTEVATeva Pharmaceutical Industries3.3651 of 5 stars$17.92+5.8%$24.43+36.4%+4.4%$20.31B$16.62B-12.3636,800Trending NewsSMMTSummit Therapeutics3.2112 of 5 stars$25.26+5.4%$37.40+48.1%+440.8%$18.76B$700,000.00-90.21110Positive NewsITCIIntra-Cellular Therapies0.8729 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.3394 of 5 stars$19.93+2.9%$39.17+96.5%-32.7%$12.78B$21.64B11.451,660News CoveragePositive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.3647 of 5 stars$13.93+3.9%$17.00+22.1%+5.8%$11.62B$311.31B22.1724,800Positive NewsVTRSViatris2.1287 of 5 stars$8.96+2.2%$10.50+17.2%-20.2%$10.63B$14.33B-12.1137,000Trending NewsMRNAModerna4.5307 of 5 stars$25.70+6.0%$53.95+109.9%-80.1%$9.94B$3.14B-2.773,900Trending NewsQGENQiagen4.0485 of 5 stars$42.92+2.5%$48.42+12.8%-3.7%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.549 of 5 stars$154.43+2.1%$216.07+39.9%+32.4%$9.42B$368.70M-21.75640Positive NewsROIVRoivant Sciences2.0157 of 5 stars$10.99+3.3%$17.50+59.2%-3.5%$7.84B$122.59M-73.26860Positive News Related Companies and Tools Related Companies TEVA Competitors SMMT Competitors ITCI Competitors GMAB Competitors RDY Competitors VTRS Competitors MRNA Competitors QGEN Competitors ASND Competitors ROIV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNTH) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
